Free Trial
NASDAQ:GHRS

GH Research (GHRS) Stock Price, News & Analysis

GH Research logo
$11.06 -1.19 (-9.71%)
Closing price 03/28/2025 04:00 PM Eastern
Extended Trading
$11.04 -0.02 (-0.14%)
As of 03/28/2025 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About GH Research Stock (NASDAQ:GHRS)

Key Stats

Today's Range
$10.87
$12.20
50-Day Range
$8.78
$17.99
52-Week Range
$6.00
$20.50
Volume
125,808 shs
Average Volume
165,027 shs
Market Capitalization
$575.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.86
Consensus Rating
Buy

Company Overview

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). The company's lead program is GH001, an inhalable mebufotenin product candidate, currently under Phase 2b clinical trial for the treatment of patients with TRD, as well as Phase 2a clinical trials for the treatment of Bipolar II disorder and postpartum depression. It is also involved in the development of GH002, an intravenous mebufotenin product candidate for IV administration, currently under Phase 1 clinical trials for the treatment of psychiatric or neurological disorder; and GH003, an intranasal mebufotenin product candidate for nasal administration, which is currently in preclinical development with a focus on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Remove Ads

GH Research Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
50th Percentile Overall Score

GHRS MarketRank™: 

GH Research scored higher than 50% of companies evaluated by MarketBeat, and ranked 515th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    GH Research has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    GH Research has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about GH Research's stock forecast and price target.
  • Earnings Growth

    Earnings for GH Research are expected to decrease in the coming year, from ($0.80) to ($1.05) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of GH Research is -14.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of GH Research is -14.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about GH Research's valuation and earnings.
  • Percentage of Shares Shorted

    7.12% of the float of GH Research has been sold short.
  • Short Interest Ratio / Days to Cover

    GH Research has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in GH Research has recently increased by 0.70%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    GH Research does not currently pay a dividend.

  • Dividend Growth

    GH Research does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.12% of the float of GH Research has been sold short.
  • Short Interest Ratio / Days to Cover

    GH Research has a short interest ratio ("days to cover") of 6.2.
  • Change versus previous month

    Short interest in GH Research has recently increased by 0.70%, indicating that investor sentiment is decreasing.
  • News Sentiment

    GH Research has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for GH Research this week, compared to 3 articles on an average week.
  • Search Interest

    Only 1 people have searched for GHRS on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added GH Research to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, GH Research insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    41.60% of the stock of GH Research is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    56.90% of the stock of GH Research is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about GH Research's insider trading history.
Receive GHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GH Research and its competitors with MarketBeat's FREE daily newsletter.

GHRS Stock News Headlines

GH Research initiated with a Buy at Guggenheim
Guggenheim starts GH Research at Buy, sees long-term upside potential
The Dirty Secret About Gold Mining Stocks...
Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy shareholder value over time. Even as gold prices rise.
GH Research initiated with an Outperform at RBC Capital
Psychedelic: GH Research, Compass Pathways report earnings results
See More Headlines

GHRS Stock Analysis - Frequently Asked Questions

GH Research's stock was trading at $7.00 at the beginning of 2025. Since then, GHRS shares have increased by 58.0% and is now trading at $11.06.
View the best growth stocks for 2025 here
.

GH Research PLC (NASDAQ:GHRS) announced its earnings results on Thursday, February, 27th. The company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.06.

GH Research (GHRS) raised $150 million in an IPO on Friday, June 25th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share.

GH Research's top institutional investors include Lynx1 Capital Management LP (9.34%), Diadema Partners LP (0.20%), Woodline Partners LP (0.15%) and Geode Capital Management LLC (0.14%).

Shares of GHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that GH Research investors own include Baidu (BIDU), Shopify (SHOP), Bristol-Myers Squibb (BMY), Zoom Video Communications (ZM), Atai Life Sciences (ATAI), CRISPR Therapeutics (CRSP) and Caesars Entertainment (CZR).

Company Calendar

Last Earnings
2/27/2025
Today
3/29/2025
Next Earnings (Estimated)
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GHRS
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$30.86
High Stock Price Target
$40.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+179.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-35,590,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
30,384,000
Market Cap
$575.43 million
Optionable
Optionable
Beta
0.94
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (NASDAQ:GHRS) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners